Thus, the aim of this study was to validate the role of previously identified SNPs in predicting resistance to R-CHOP, in an independent suitable case series of DLBCL treated with R-CHOP that we enrolled in the framework of a pharmacogenetic study[57]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.